Article
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.
Antimicrobial agents and chemotherapy - 1 Sept 2015
Krishnan Preethi, Tripathi Rakesh, Schnell Gretja, Reisch Thomas, Beyer Jill, Irvin Michelle, Xie Wangang, Larsen Lois, Cohen Daniel, Podsadecki Thomas, Pilot-Matias Tami, Collins Christine
Abstract excerpt
AVIATOR, a phase 2 clinical trial, evaluated ritonavir-boosted paritaprevir (a protease inhibitor), ombitasvir (an NS5A inhibitor), and dasabuvir (a nonnucleoside polymerase inhibitor) (the three-drug [3D] regimen) with or without ribavirin (RBV) for 8, 12, or 24 weeks in 406 HCV genotype 1 (GT1)-infected patients. The rate of sustained virologic response 24 weeks after treatment ranged from 88% to 100% across...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.